SCHEMBL30833288

SCHEMBL30833288

CN1C(=O)CC(=O)c2nc(-c3cncs3)ncc21

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 1/20 0.36
TBXAS1 P24557 1/20 0.35
BMPR1B O00238 4/20 0.32
BMPR1A P36894 4/20 0.32
ACVRL1 P37023 4/20 0.32
ACVR1 Q04771 4/20 0.32
TGFBR1 P36897 3/20 0.32
CDC25A P30304 1/20 0.32
CDC25B P30305 1/20 0.32
CDC25C P30307 1/20 0.32
DUSP3 P51452 1/20 0.32
GABRA1 P14867 1/20 0.31
GABRG2 P18507 1/20 0.31
GABRB3 P28472 1/20 0.31
GABRA5 P31644 1/20 0.31
GABRA3 P34903 1/20 0.31
GABRA2 P47869 1/20 0.31
CD38 P28907 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29769797 0.67 CD38 (0.35) CD38
SCHEMBL29769801 0.64 TRIM24 (0.40) TRIM24BMPR1BBMPR1AACVRL1ACVR1
SCHEMBL30261739 0.62 TBXAS1 (0.35) TBXAS1CD38
SCHEMBL29764153 0.61 TRIM24 (0.40) TRIM24BMPR1BBMPR1AACVRL1ACVR1
SCHEMBL21831489 0.61 TRIM24 (0.40) TRIM24BMPR1BBMPR1AACVRL1ACVR1
SCHEMBL29769804 0.61 CD38 (0.44) TBXAS1CD38
SCHEMBL12945553 0.60 CD38 (0.35) TBXAS1CD38
SCHEMBL12364215 0.59 ACVRL1 (0.46) TRIM24BMPR1BBMPR1AACVRL1ACVR1
SCHEMBL23564216 0.58 TRIM24 (0.37) TRIM24BMPR1BBMPR1AACVRL1ACVR1
SCHEMBL30540203 0.58 S100A4 (0.41) CD38

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4284511-B1 AZAQUINOLINES AS INHIBITORS OF CD38 BOEHRINGER INGELHEIM INT (DE) 2025-07-16 EP disclosed
US-20240279224-A1 QUINOLINES AND AZAQUINOLINES AS INHIBITORS OF CD38 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-08-22 US disclosed
CN-117580829-A Quinoline and azaquinolines as inhibitors of CD38 勃林格英格翰国际有限公司 2024-02-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240279224-A1 QUINOLINES AND AZAQUINOLINES AS INHIBITORS OF CD38 CD38, NQO1, NQO2 TRIM24 3511/4885TBXAS1 2337/4885BMPR1B 4679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.